Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 09

24P - Single cell transcriptomics of the immune cells during chemotherapy in triple-negative breast cancer patients

Date

21 Oct 2023

Session

Poster session 09

Topics

Cancer Biology;  Tumour Immunology;  Pathology/Molecular Biology;  Molecular Oncology;  Therapy

Tumour Site

Breast Cancer

Presenters

Anastasia Frolova

Citation

Annals of Oncology (2023) 34 (suppl_2): S187-S214. 10.1016/S0923-7534(23)01931-2

Authors

A. Frolova1, T.S. Gerashchenko2, M. Patysheva1, A.A. Fedorov2, O. Bragina3, E. Garbukov4, N. Cherdyntseva1, V.Y. Korobeynikov2

Author affiliations

  • 1 Laboratory Of Molecular Oncology And Immunology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009 - Tomsk/RU
  • 2 Laboratory Of Cancer Progression Biology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009 - Tomsk/RU
  • 3 Department Of Radionuclide Therapy And Diagnostics, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009 - Tomsk/RU
  • 4 Department Of General Oncology, Cancer Research Institute, Tomsk National Research Medical Center of the Russian Academy of Sciences, 634009 - Tomsk/RU

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 24P

Background

Chemotherapy is the mainstay of systemic treatment for patients with triple-negative breast cancer (TNBC) due to the lack of targets for targeted therapy (HER2/neu; ER; PR). Components of the immune system are known to be involved in the response to chemotherapeutic treatment. Here we aimed to study the dynamics of changes in immune cell composition during neoadjuvant chemotherapy (NACT).

Methods

The immune cells were purified from peripheral blood and biopsy samples of 5 TNBC patients before NACT and 21st days of first course of NACT (AC regimen). Total cell concentration and viability (Calcein/DRAQ7) were assessed by flow cytometry (Cytoflex, Beckman Coulter). Single cells were sequenced on a Genolab M platform (GeneMind Biosciences) using 10x Genomics technology for fixed multiplexed samples. Data were analyzed using Seurat and SingleR.

Results

Sequencing revealed a variety of immune cell populations including: B cells, DC cells, NK cells, CD4+, CD8+ and T regulatory lymphocytes, classical and non-classical monocytes, granulocytes and others. In the blood, the pool of classical monocytes and NK cells were depleted up to day 21 after the first NACT cycle, while naive CD4+, CD8+ T cells and end effector CD8+ T cells, were increased by day 21. In the populations of monocytes and NK cells overexpression of RGS2, ANXA1, FGL2, MX1, IFI6 genes were observed, involved in induction apoptosis. CD8+T-cells, as well as Th-1 and Th-2 CD4+ T-cells were characterized by increased expression of NFKBIA, JUN, FOS, involved in T cell differentiation. In the tumor microenvironment, depletion of CD4+ T cells, CD8+ T cells and memory B cells and an increase in T-regulatory cells and plasma cells were observed. DUSP4, LCK, CXCR4, LTB, TNFRSF18, IL2RB and PTPN7 genes were overexpressed and involved in the regulation of cytokine secretion and inhibition of TCR signaling in CD4+ and CD8+ T cells; chemotaxis-mediated inflammation in memory B cells; T cells differentiation, and induction of invasion/migration of tumor cells in T-regulatory cells and plasma cells.

Conclusions

The first cycle of NACT induced renewal of the immune cells’ composition in the blood and tumor microenvironment skewing towards to immune disfunction.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Cancer Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences, Tomsk, Russian Federation.

Funding

Russian Science Foundation (grant #22-75-10128).

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.